This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2008 Jun 19;358(25):2704-15.

doi: 10.1056/NEJMra072739.

Cancer immunology

Olivera J Finn¹

Affiliations

PMID: 18565863
DOI: 10.1056/NEJMra072739

Review

Cancer immunology

Olivera J Finn. N Engl J Med. 2008.

. 2008 Jun 19;358(25):2704-15.

doi: 10.1056/NEJMra072739.

Author

Olivera J Finn¹

Affiliation

¹ Department of Immunology, University of Pittsburgh School of Medicine, E1044, Biomedical Science Tower, Pittsburgh, PA 15261, USA. ojfinn@pitt.edu

PMID: 18565863
DOI: 10.1056/NEJMra072739

No abstract available

PubMed Disclaimer

Comment in

Cancer immunotherapy--the endgame begins.
Weiner LM. Weiner LM. N Engl J Med. 2008 Jun 19;358(25):2664-5. doi: 10.1056/NEJMp0803663. N Engl J Med. 2008. PMID: 18565858 Free PMC article. No abstract available.
Cancer immunotherapy.
Rosenberg SA, Dudley ME, Restifo NP. Rosenberg SA, et al. N Engl J Med. 2008 Sep 4;359(10):1072. doi: 10.1056/NEJMc081511. N Engl J Med. 2008. PMID: 18768956 Free PMC article. No abstract available.

Similar articles

Tumor immunology top 10 list.
Finn OJ. Finn OJ. Immunol Rev. 2008 Apr;222:5-8. doi: 10.1111/j.1600-065X.2008.00623.x. Immunol Rev. 2008. PMID: 18363991 No abstract available.
Introduction: Cancer Immunology Special Issue-Immunotherapy.
Kawakami Y. Kawakami Y. Int Immunol. 2016 Jul;28(7):317. doi: 10.1093/intimm/dxw028. Epub 2016 Jun 15. Int Immunol. 2016. PMID: 27313100 No abstract available.
From therapeutic monoclonal antibodies to therapeutic vaccines for cancer.
Berinstein NL. Berinstein NL. Hum Vaccin. 2009 Jun;5(6):364-7. doi: 10.4161/hv.8990. Hum Vaccin. 2009. PMID: 19694082 No abstract available.
Future Research Goals in Immunotherapy.
Hulett TW, Fox BA, Messenheimer DJ, Marwitz S, Moudgil T, Afentoulis ME, Wegman KW, Ballesteros-Merino C, Jensen SM. Hulett TW, et al. Surg Oncol Clin N Am. 2019 Jul;28(3):505-518. doi: 10.1016/j.soc.2019.02.006. Epub 2019 Apr 12. Surg Oncol Clin N Am. 2019. PMID: 31079803 Review.
Cancer immunotherapy comes of age.
Mellman I, Coukos G, Dranoff G. Mellman I, et al. Nature. 2011 Dec 21;480(7378):480-9. doi: 10.1038/nature10673. Nature. 2011. PMID: 22193102 Free PMC article. Review.

See all similar articles

Cited by

A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer.
Smith JP, Harms JF, Matters GL, McGovern CO, Ruggiero FM, Liao J, Fino KK, Ortega EE, Gilius EL, Phillips JA 3rd. Smith JP, et al. Cancer Biol Ther. 2012 Feb 1;13(3):164-74. doi: 10.4161/cbt.13.3.18698. Epub 2012 Feb 1. Cancer Biol Ther. 2012. PMID: 22277584 Free PMC article.
Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa/HIF2α and estrogen receptor β signals.
Song W, Yeh CR, He D, Wang Y, Xie H, Pang ST, Chang LS, Li L, Yeh S. Song W, et al. Oncotarget. 2015 Aug 7;6(22):19290-304. doi: 10.18632/oncotarget.4478. Oncotarget. 2015. PMID: 26079540 Free PMC article.
Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy.
Butts CA. Butts CA. Transl Lung Cancer Res. 2013 Oct;2(5):415-22. doi: 10.3978/j.issn.2218-6751.2013.10.09. Transl Lung Cancer Res. 2013. PMID: 25806261 Free PMC article. Review.
Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Lazăr DC, Avram MF, Romoșan I, Cornianu M, Tăban S, Goldiș A. Lazăr DC, et al. World J Gastroenterol. 2018 Aug 28;24(32):3583-3616. doi: 10.3748/wjg.v24.i32.3583. World J Gastroenterol. 2018. PMID: 30166856 Free PMC article. Review.
Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors.
Lu JC, Zeng HY, Sun QM, Meng QN, Huang XY, Zhang PF, Yang X, Peng R, Gao C, Wei CY, Shen YH, Cai JB, Dong RZ, Shi YH, Sun HC, Shi YG, Zhou J, Fan J, Ke AW, Yang LX, Shi GM. Lu JC, et al. Theranostics. 2019 Jul 9;9(16):4678-4687. doi: 10.7150/thno.36276. eCollection 2019. Theranostics. 2019. PMID: 31367249 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- ClinicalTrials.gov